



Europass Curriculum Vitae

Personal information

Surname(s) / First name(s) **Bergamini Cristiana**
Address(es) Hospital: Fondazione IRCCS Istituto Nazionale Tumori, via G. Venezian 1
20133 Milan, Italy
Telephone(s) Hospital: +39 02 23902150
Fax(es) Hospital: +39 02 23903769
E-mail cristiana.bergamini@istitutotumori.mi.it
Nationality Italian
Date of birth 08 February 1976
Gender Female

Work experience

Dates From December 2007
Title of qualification awarded **Associate Physician in Oncology** (Head and Neck Cancer Unit,
directed by Prof. Lisa Licitra)
Principal subjects/occupational skills covered Clinical Oncology
Name and type of organization providing education and training IRCCS Fondazione Istituto Nazionale per lo Studio e la Cura dei Tumori,
via G. Venezian 1, 20133 Milan, Italy
Type of business Medical oncology involved in patients with head and neck tumor care

Dates From July 2004
Occupation or position held Full staff position as Medical Oncologist
Main activities and responsibilities **Interdisciplinary group work** (surgeon, radiotherapist, radiologist,
medical oncologist)
Name and address of employer Discussant (weekly seminars)
Name and type of organization providing education and training IRCCS Fondazione Istituto Nazionale per lo Studio e la Cura dei Tumori,
via G. Venezian 1, 20133 Milan, Italy
Type of business Head and neck cancer

Education and training

Dates	13 November 2007
Title of qualification awarded	Board certificate in Clinical Oncology (cum laude)
Principal subjects/occupational skills covered	Clinical Oncology
Name and type of organization providing education and training	Università degli Studi, Milan, Italy
Level in national or international classification	ISCED 5A (Field of Education: 72)
Dates	From 1 June 2007 to 30 November 2007
Occupation or position held	Full staff Associate Physician
Main activities and responsibilities	Full staff positions as Physician
Name and address of employer	Department, Hospital Gustave Roussy, Villejuif, France
Type of business or sector	Health care: radiotherapy of the breast cancer
Dates	From 1 July 2004 to 30 May 2007
Title of qualification awarded	Clinical Fellow Associate Physician in Clinical Oncology
Principal subjects/occupational skills covered	Clinical Oncology
Name and type of organization providing education and training	IRCCS Fondazione Istituto Nazionale per lo Studio e la Cura dei Tumori, via G. Venezian 1, 20133 Milan, Italy
Type of business	Medical oncology involved in patients with head and neck tumor care
Dates	16 July 2004
Title of qualification awarded	Italian General Medicine License
Principal subjects/occupational skills covered	General Medicine
Name and type of organization providing education and training	Università degli Studi, Milan, Italy (number of medical license 006206)
Level in national or international classification	ISCED 5A (Field of Education: 72)
Dates	From June 2004 to July 2004
Title of qualification awarded	Apprenticeship in General Medicine
Principal subjects/occupational skills covered	General Medicine (hepatic disease)
Name and type of organization providing education and training	San Paolo Hospital, Milan, Italy
Level in national or international classification	ISCED 5A (Field of Education: 72)
Dates	From April 2004 to May 2004
Title of qualification awarded	Apprenticeship in General Medicine
Principal subjects/occupational skills covered	Surgery
Name and type of organization providing education and training	San Paolo Hospital, Milan, Italy

Level in national or international classification ISCED 5A (Field of Education: 72)

Dates 17 March 2004

Title of qualification awarded **Italian Medical License**

Principal subjects/occupational skills covered Medicine

Name and type of organization providing education and training Università degli Studi, Milan, Italy

Level in national or international classification ISCED 5A (Field of Education: 72)

Dates From 1 January 2001 to 16 March 2004

Title of qualification awarded **Apprenticeship**

Principal subjects/occupational skills covered Medical Oncology

Name and type of organization providing education and training Fondazione Ospedale Maggiore Policlinico, Milan, Italy

Level in national or international classification ISCED 5A (Field of Education: 72)

Dates From 1990 to 1995

Title of qualification awarded **College Degree** (cum maximum mark: 60/60)

Principal subjects/occupational skills covered High Scientific School

Name and type of organisation providing education and training Liceo Scientifico Lussana, Bergamo, Italy

Level in national or international classification ISCED 5A (Field of Education: 72)

Personal skills and competences

Mother tongue(s) Italian

Other language(s) English; French

Self-assessment European level (*)

English

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
A1	Proficient user	A1	Proficient user	A1	Proficient user	A1	Proficient user	A1	Proficient user

(*) Common European Framework of Reference for Languages

Self-assessment European level (*)

French

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user

(*) Common European Framework of Reference for Languages

Additional information

She is involved in all institutional research activities on head and neck tumor.

She is the sub-Investigator of several Italian and International trials on head and neck cancer treatment. She has experience in the management of clinical trials (latest GCP Training Certificate is dated 24 February 2017).

She collaborates in the efficient and effective management of phase I clinical trials (latest Training Certificate is dated 9 June 2017).

She has Certification in the Basic Life Support BLS Course (latest BLS Training Certificate is dated 22 May 2017).

She is member of the following professional/scientific society: NICSO, Network Italiano Cure di Supporto in Oncologia.

She is registered in Italian Network on Rare Tumors (Rete Tumori Rari), a collaborative effort among Italian cancer centers, which tries to exploit distant patient sharing in order to improve quality of care and diminish health migration for rare solid cancers.

Publications

See Annexes

Orcid ID: <http://orcid.org/0000-0001-7616-5125>

Other IDs [Scopus Author ID: 8905689200](#)

H-Index (according to Scopus) = 13

Document by author = 43

Total number of citations = 924

Participation

Participation to project I.P.P.O.C.R.A.T.E.S. Research “Ho bisogno di te anche le parole curano” (dedicated to the detection of both the relational needs of patients, both the attitudes of doctors toward relationship. 30/01/2014

Annexes

Annex 1: List of Medline-indexed scientific publications, in English

Annex 2: List of Abstract, in English

Annex 3: List of Abstract, in Italian Language

Annex 4: HAND-BOOK, in English

Annex 5: HAND-BOOK, in Italian Language

Annex 6: List of Clinical Trials

Annex 7: Congress

Knowledge

She is able to use the most important Microsoft programs.

Annex 1: List of Medline-indexed scientific publications, in English:

- 1. Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events.**
Grisanti S, Bianchi S, Locati LD, Triggiani L, Vecchio S, Bonetta A, Bergamini C, Conte P, Airoldi M, Merlano M, Carlini P, Ibrahim T, Rossetto C, Alfieri S, Pronzato P, Tonoli S, Maroldi R, Nicolai P, Resteghini C, Magrini SM, Berruti A.
PLoS One. 2019 Mar 20;14(3):e0213934.
- 2. Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?**
Cavalieri S, Platini F, Bergamini C, Resteghini C, Galbiati D, Bossi P, Perrone F, Tamborini E, Quattrone P, Licitra L, Locati LD, Alfieri S.
Expert Opin Investig Drugs. 2019 Mar 22:1-9.
- 3. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.**
van Boxtel W, Locati LD, van Engen-van Grunsven ACH, Bergamini C, Jonker MA, Fiets E, Cavalieri S, Tooten S, Bos E, Quattrone P, Verhaegh GW, Schalken JA, Licitra L, van Herpen CML; PALGA Group.
Eur J Cancer. 2019 Feb 13;110:62-70.
- 4. The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.**
Siano M, Alfieri S, Granata R, Calareso G, Orlandi E, Bergamini C, Locati LD.
Tumori. 2019 Feb 19.
- 5. Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck.**
Mirabile A, Miceli R, Calderone RG, Locati L, Bossi P, Bergamini C, Granata R, Perrone F, Mariani L, Licitra L.
Head Neck. 2019 Jan 16.
- 6. Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients.**
Orlandi E, Iacovelli NA, Rancati T, Cicchetti A, Bossi P, Pignoli E, Bergamini C, Licitra L, Fallai C, Valdagni R, Cavallo A.
Oral Oncol. 2018 Nov;86:266-272.
- 7. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.**
Cavalieri S, Perrone F, Miceli R, Ascierio PA, Locati LD, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi P.
Eur J Cancer. 2018 Jul;97:7-15.
- 8. Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers.**
Resteghini C, Perrone F, Miceli R, Bergamini C, Alfieri S, Orlandi E, Guzzo M, Granata R, Galbiati D, Cavalieri S, Locati L, Licitra L, Bossi P.
Tumori. 2018 Jun;104(3):213-220.
- 9. Lenvatinib-induced renal failure: two first-time case reports and review of literature.**
Cavalieri S, Cosmai L, Genderini A, Nebuloni M, Tosoni A, Favales F, Pistillo P, Bergamini C, Bossi P, Licitra L, Locati LD, Alfieri S.
Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):379-385.
- 10. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.**
Cavalieri S, Rivoltini L, Bergamini C, Locati LD, Licitra L, Bossi P.
Cancer Treat Rev. 2018 Apr;65:78-86
- 11. Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience.**
Alfieri S, Bergamini C, Granata R, Locati L, Licitra L, Bossi P.

- 12. Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?**
Bossi P, Siano M, Bergamini C, Cossu Rocca M, Sponghini AP, Giannoccaro M, Tonella L, Paoli A, Marchesi E, Perrone F, Pilotti S, Locati LD, Canevari S, Licitra L, De Cecco L.
Disease Markers. Volume 2017, Article ID 6870614, page 9.
- 13. A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin.**
Bossi P, Cortinovis D, Fatigoni S, Cossu Rocca M, Fabi A, Seminara P, Ripamonti C, Alfieri S, Granata R, Bergamini C, Agustoni F, Bidoli P, Nolè F, Pessi MA, Macchi F, Michellini L, Montanaro F, Roila F.
Ann Oncol. 2017 Oct 1;28(10):2547-2551.
- 14. RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target?**
Carlo Resteghini, Salvatore Alfieri, Pasquale Quattrone, Francesca Dominoni, Giovanna Garzone, Ester Orlandi, Laura Locati, Cristiana Bergamini, Donata Galbiati, Nicola Alessandro Iacovelli, Carlo Fallai, Lisa Licitra and Paolo Bossi.
Oncotarget, 2017, Vol. 8, (No. 56), pp: 96184-96189.
- 15. Do not throw the baby out with the bathwater: SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding.**
Resteghini C, Locati LD, Bossi P, Bergamini C, Guzzo M, Licitra L.
Ann Oncol. 2017 Sep 1;28(9):2321-2322.
- 16. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.**
Specenier PM, Remenar E, Buter J, Schrijvers DL, Bergamini C, Licitra LF, Awada A, Clement PM, Fortpied C, Menis J, Vermorken JB.
Ann Oncol. 2017 Sep 1;28(9):2219-2224.
- 17. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area**
Alfieri S, Iacovelli NA, Marcegaglia S, Lasorsa I, Resteghini C, Taverna F, Mazzocchi A, Orlandi E, Guzzo M, Bianchi R, Fanti D, Pala L, Racca S, Dvir R, Quattrone P, Gloghini A, Volpi CC, Granata R, Bergamini C, Locati L, Licitra L, Bossi P.
Oncotarget. 2017 Jul 18;8(29):47780-47789.
- 18. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients**
Resteghini C, Cavaliere S, Galbiati D, Granata R, Alfieri S, Bergamini C, Bossi P, Licitra L, Locati LD.
Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):349-361.
- 19. Preemptive treatment with Xonrid®, a medical device to reduce radiation induced dermatitis in head and neck cancer patients receiving curative treatment: a pilot study.**
Iacovelli NA, Naimo S, Bonfantini F, Cavallo A, Bossi P, Fallai C, Pignoli E, Alfieri S, Bergamini C, Favales F, Orlandi E.
Support Care Cancer. 2017 Jun;25(6):1787-1795.
- 20. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy.**
Siano M, Infante G, Resteghini C, Cau MC, Alfieri S, Bergamini C, Granata R, Miceli R, Locati L, Licitra L, Bossi P.
Oral Oncol. 2017 Jun;69:33-37.
- 21. Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?**
Alfieri S, Granata R, Bergamini C, Resteghini C, Bossi P, Licitra LF, Locati LD.
Oral Oncol. 2017 Mar; 66:58-63.
- 22. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.**

Locati LD, Perrone F, Cortelazzi B, Bergamini C, Bossi P, Civelli E, Morosi C, Lo Vullo S, Imbimbo M, Quattrone P, Dagrada GP, Granata R, Resteghini C, Mirabile A, Alfieri S, Orlandi E, Mariani L, Saibene G, Pilotti S, Licitra L.
Eur J Cancer. 2016 Dec;69:158-16

- 23. Safety of combination treatment with imatinib mesylate, carboplatin, and cetuximab in a patient with multiple cancers: a case report.**
Pala L, Bergamini C, Imbimbo M, Granata R, Locati L, Alfieri S, Licitra L, Bossi P.
Tumori. 2016 Nov 11;102(Suppl. 2).
- 24. Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therap**
Bossi P, Bergamini C, Miceli R, Cova A, **Orlandi E**, Resteghini C, Locati L, Alfieri S, Imbimbo M, Granata R, Mariani L, Iacovelli NA, Huber V, Cavallo A, Licitra L, Rivoltini L.
Int J Radiat Oncol Biol Phys. 2016 Sep. Volume 96, Issue 5, 1 December 2016, Pages 959-966
- 25. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.**
Bossi P, Bergamini C, Siano M, Cossu Rocca M, Sponghini AP, Favales F, Giannoccaro M, Marchesi E, Cortelazzi B, Perrone F, Pilotti S, Locati LD, Licitra L, Canevari S, De Cecco L.
Clin Cancer Res. 2016 Aug 1;22(15):3961-70.
- 26. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor – positive salivary gland cancers.**
Laura D Locati, Federica Perrone, Barbara Cortelazzi, Salvatore Lo Vullo, Paolo Bossi, Giampaolo Dagrada, Pasquale Quattrone. Cristiana Bergamini, Paolo Potepan, Enrico Civelli, Carlo Fallai, Silvana Pilotti, Lisa Licitra.
Head and Neck, May 2016, 724 – 731.
- 27. Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer.**
Alfieri S, Ripamonti CI, Marcegaglia S, **Orlandi E**, Iacovelli NA, Granata R, Cavallo A, Pozzi P, Boffi R, Bergamini C, Imbimbo M, Pala L, Resteghini C, Mirabile A, Locati LD, Licitra L, Bossi P.
Head Neck. 2016 Apr;38 Suppl 1:E1521-7
- 28. Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy.**
Mirabile A, Vismara C, Crippa F, Bossi P, Locati L, Bergamini C, Granata R, Resteghini C, Conte E, Morelli D, Scarpellini P, Licitra L.
Head Neck. 2016 Apr;38 Suppl 1:E1009-13.
- 29. New toxicity profile for novel immunotherapy agents: focus on immune – checkpoint inhibitors.**
Ciccarese C, Alfieri S, Santoni M, Santini D, Brunelli M, Bergamini C, Licitra L, Montinori R, Tortora G, Massari F.
Expert Opinion On Drug Metabolism and Toxicology, 2016 Jan;12(1):57-75.
- 30. Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?**
Bergamini C, Locati L, Bossi P, Granata R, Alfieri S, Resteghini C, Imbimbo M, Fallai C, Orlandi E, Tana S, Iacovelli NA, Guzzo M, Ibba T, Colombo S, Bianchi R, Pizzi N, Fontanella W, Licitra L.
Oral Oncol. 2016 Jan 13.
- 31. Nasopharyngeal carcinoma associated with epithelioid cell granulomatous reaction: a case report.**
Bergamini C, Orlandi Ester, Bossi P, Guzzo M, Iacovelli NA, Quattrone P, Pellegrinelli A, Licitra L.
Journal of Nasopharyngeal Carcinoma Editorial Office 2015; N. 2.
- 32. Health care – associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy.**
Aurora Mirabile, Chiara Vismara, Fulvio Crippa, Paolo Bossi, Laura Locati, Cristiana Bergamini, Roberta Granata, Carlo Resteghini, Eutilia Conte, Daniele Morelli, Paolo Scarpellini, Lisa Licitra.
Head and neck, 22 June 2015; 1 – 6.

- 33. Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review.**
Ester Orlandi, Silvia Takanen, Tommaso Giandini, Eva Iannacone, Walter Fontanella, Laura Locati, Mauro Carrara, Paolo Bossi, Cristiana Bergamini, Roberta Granata, Vincenzo Tombolini, Tullio Ibba, Lisa Licitra, Emanuele Pignoli.
Future Oncol. 2014 Nov;10(14):2111-20.
- 34. Fentanyl nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer.**
Bossi P, Locati L, Bergamini C, Mirabile A, Granata R, Imbimbo M, Resteghini C, Licitra L.
Oral Oncol. 2014 Sep;50(9):884-7.
- 35. Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma.**
Orlandi E, Tomatis S, Potepan P, Bossi P, Mongioj V, Carrara M, Palazzi M, Franceschini M, Bergamini C, Locati L, Iannacone E, Guzzo M, Ibba T, Crippa F, Licitra L, Pignoli E, Fallai C.
Future Oncol. 2013 Jan;9(1):103-14
- 36. Tumor stage, human papilloma virus and smoking status affect the survival of patient with oropharyngeal cancer: an Italian validation study.**
Granata R, Miceli R, Orlandi E, Cortelazzi B, Franceschini M, Locati LD, Bossi P, Bergamini C, Mirabile A, Mariani L, Olmi P, Scaramellini G, Potepan P, Quattrone P, Ang KK & Licitra L.
Annals of Oncology advance Acces published December 21, 2011.
- 37. Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by Intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer.**
P Bossi, E Orlandi, C Bergamini, L Locati, R Granata, A Mirabile, D Parolini, M Franceschini, C Fallai, P Olmi, P Quattrone, P Potepan, A Gloghini, L Mariani, R Miceli, L Licitra.
Annals of Oncology 22: 2495 – 2500, 2011.
- 38. Target therapy in head and neck cancer (HNC).**
Lisa Licitra, Cristiana Bergamini, Aurora Mirabile, Roberta Granata.
Current opinion in Otolaryngology and Head and Neck Surgery. 2011 Apr; 19(2):132-7.
- 39. Comment on "Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysis", by Rades et coll.**
Bossi P, Granata R, Bergamini C, Mirabile A, Locati L, Licitra L.
Oral Oncology, 2010 Oct 15, 46, 888.
- 40. Indications to percutaneous fluoroscopic gastrostomy in palliative head and neck cancer patients.**
Alessandro Sironi, Claudia Arcovio, Cristiana Bergamini, Silvia Colatruglio, Cecilia Gavazzi
Nutritional Therapy and Metabolism, 2010: 28(3), 143 – 147.
- 41. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).**
Locati LD, Perrone F, Losa M, Mela M, Casieri P, Orsenigo M, Cortelazzi B, Negri T, Tamborini E, Quattrone P, Bossi P, Rinaldi G, Bergamini C, Calderone RG, Liberatoscioli C, Licitra L.
Oral Oncol, 2009 Nov; 45(11):986-90.
- 42. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study.**
Locati L, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S and Licitra L.
Oral Oncology, 2009 Jul;45(7):574-8.
- 43. Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system.**
Palazzi M, Tomatis S, Orlandi E, Guzzo M, Sangalli C, Potepan P, Fantini S, Bergamini C, Gavazzi C, Licitra L, Scaramellini G, Cantù G, and Olmi P.
International Journal of Radiation Oncology, Biology, Physical, 2008 Feb 1; 70(2):330-7.
- 44. Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients.**

Bossi P, Liberatoscioli C, Bergamini C, Locati LD, Fava S, Rinaldi G, Orlandi E, Olmi P, Tagliabue E, Ménard S, Licitra L.
Annals of Oncology, 2007 Mar;18(3):601-2.

45. High-Risk Human Papilloma Virus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma.

Lisa Licitra, Federica Perrone, Paolo Bossi, Simona Suardi, Luigi Mariani, Raffaella Artusi, Maria Oggioni, Chiara Rossini, Giulio Cantù, Massimo Squadrelli, Pasquale Quattrone, Laura D. Locati, Cristiana Bergamini, Patrizia Olmi, Marco A. Pienotti, and Silvana Pilotti.
Journal of Clinical Oncology, vol 24, Num 36, Dec 20, 2006; 5630 – 5636.

46. Is restoring Platinum Sensitivity the Best Goal for Cetuximab in Recurrent/Metastatic Nasopharyngeal Cancer?

Lisa Licitra, Paolo Bossi, Laura D. Locati, Cristiana Bergamini.
Journal of Clinical Oncology, Vol 23, No 30 (October 20), 2005: pp. 7757 – 7758.

47. Is PSA useful in the diagnosis and monitoring of parotid adenocarcinomas?

Cristiana Bergamini, Marta Barisella, Laura D. Locati, Palo Bossi, Paolo Potepan, Gaetana Rinaldi, Lisa Licitra.
Oral Oncology EXTRA (2005) 41, 219–221

Annex 2: List of **ABSTRACT**, in English:

- 1. Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI).**
Salvatore Alfieri, Roberto Ferrara, Giuseppina Calareso, Stefano Cavaliere, Francesca Platini, Moela Mancinelli, Carlo Resteghini, Ester Orlandi, Nicola Alessandro Iacovelli, Letizia Ferella, Cesare Piazza, Giulia Apollonio, Donata Galbiati, Paolo Bossi, Cristiana Bergamini, Laura Deborah Locati, Lisa F. Licitra
Accepted for *POSTER SESSION* at the ASCO (American Society of Clinical Oncology) Annual Meeting 2019. Abstract#260473
- 2. Clinical Prognostic Factors in patients with recurrent or metastatic carcinoma of the head and neck treated with immunotherapy**
Carlo Resteghini, Stefano Cavaliere, Alessandro Rametta, Salvatore Alfieri, Donata Galbiati, Francesca Platini, Laura Deborah Locati, Paolo Bossi, **Cristiana Bergamini**, Roberta Granata, Ester Orlandi, Cesare Piazza, Moela Mancinelli, Lisa F. Licitra
Accepted as *publication only* at the ASCO (American Society of Clinical Oncology) Annual Meeting 2019. Abstract#260325
- 3. Retrospective Analysis of baseline clinical factors associated to CDDP-nephrotoxicity in locally advanced head and neck cancer (LAHNC) patients**
Francesca Platini, Francesco Barretta, Salvatore Alfieri, Stefano Cavaliere, Carlo Resteghini, Donata Galbiati, Laura Deborah Locati, Cristiana Bergamini, Roberta Granata, Giuseppina Calareso, Nicola Alessandro Iacovelli, Pasquale Quattrone, Fabiola Incandela, Paolo Bossi, Lisa F. Licitra
Accepted as *publication only* at the ASCO (American Society of Clinical Oncology) Annual Meeting 2019. Abstract#263813
- 4. Druggable molecular targets in skin adnexal malignancies.**
Stefano Cavaliere, Federica Perrone, Pasquale Quattrone, Laura Locati, Cristiana Bergamini, Roberta Granata, Salvatore Alfieri, Carlo Resteghini, Donata Galbiati, Francesca Platini, Giuseppina Calareso, Lisa F. Licitra, Paolo Bossi.
Article in Journal of Clinical Oncology (15_suppl):e21619-e21619. May 2018.
- 5. Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aerodigestive tract (NCT02860936).**
Laura Locati, Donata Galbiati, Giuseppina Calareso, Salvatore Alfieri, Roberta Granata, Paolo Bossi, Cristiana Bergamini, Carlo Resteghini, Stefano Cavaliere, Francesca Platini, Pasquale Quattrone, Moela Mancinelli, Andrea Zucchella, Luigi Mariani, Guido Fedele, Lisa F. Licitra.
Article in Journal of Clinical Oncology 36(15_suppl):6086-6086 May 2018.
- 6. Diagnostic workup of Cervical Unknown Primary (CUP) of the head and neck (HN).**
Bergamini C, Locati L, Bossi P, Orlandi E, Piazza C, Granata R, Alfieri S, Resteghini C, Cavaliere S, Platini F, Licitra L.
Tumori Journal 2018, p147, L11.
- 7. Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment.**
Galbiati D, Cavaliere S, Alfieri S, Resteghini C, Bergamini C, Granata R, Platini F, Locati LD, Licitra L and Bossi P.
Tumori Journal 2018, p142, L02.
- 8. Adoptive T-cell therapy in relapsed EBV-related nasopharyngeal carcinoma.**
Secondino S, Bossi P, Gurrado A, Basso S, Imarisio I, Pagani A, Pisani I, Bagnarino J, Zecca M, Casanova M, Bergamini C, Perotti C, Licitra L, Comoli C and Pedrazzoli P.
Tumori Journal 2018, p163, N10.
- 9. Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer.**
R Granata, E Orlandi, G Infante, N A Iacovelli, R Miceli, A Cavallo, S Alfieri, C Bergamini, C Resteghini, D Galbiati, S Cavaliere, L Locati, S Tana, S Naimo, C Fallai, L Licitra, P Bossi.

10. **A single institution twenty-year experience of recurrent or metastatic epithelial non glandular sinonasal cancer.**
S Cavalieri, R Granata, L Locati, C Bergamini, S Alfieri, C Resteghini, D Galbiati, E Orlandi, N A Iacovelli, G Calareso, M Guzzo, P Quattrone, L Licitra, P Bossi
Annals of Oncology - Article 28(suppl_6), 2017.
11. **Gene-expression profiles of primary and metastatic lesions in head and neck squamous cell carcinoma.**
S Alfieri, P Bossi, D Galbiati, M Giannoccaro, S Pilotti, F Perrone, N Paielli, L Tonella, C Bergamini, R Granata, C Resteghini, S Cavalieri, N A Iacovelli, E Orlandi, L D Locati, L Licitra, S Canevari, L De Cecco.
Annals of Oncology - 28(suppl_6), 2017.
12. **A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma.**
P Bossi, S Cavalieri, F Perrone, R Miceli, P Ascierto, L Locati, C Bergamini, R Granata, S Alfieri, C Resteghini, D Galbiati, A Busico, N Paielli, R Patuzzo, A Maurichi, G Gallino, R Ruggeri, L Mariani, M Palla, L Licitra.
Annals of Oncology, 28(suppl_6), 2017.
13. **Sinonasal non glandular cancers relapsing after multimodal treatments**
S. Cavalieri, R. Granata, L.D. Locati, C. Bergamini, S. Alfieri, C. Resteghini, D. Galbiati, E. Orlandi, N.A. Iacovelli, G. Calareso, M. Guzzo, P. Quattrone, L. Licitra, P. Bossi.
Annals of Oncology (2017) 28 (suppl_5): v372-v394.
14. **Adjuvant androgen deprivation therapy for high-risk androgen receptor-positive salivary duct carcinoma**
W. Boxtel, L.D. Locati, S. Tooten, E. Bos, C. Bergamini, A.C.H. van Engen-van Grunsven, E. Boon, E. Fiets, S. Cavalieri, G. Verhaegh, J. Schalken, L. Licitra, C.M.L. Herpen
Annals of Oncology, 28(suppl_5), 2017: v372-v394.
15. **Natural history and prognostic factors of head and neck cancer patients with bone metastases: A retrospective Italian study.**
S. Grisanti, C. Bergamini, S. Bianchi, A. Baiguini, S. Vecchio, L.D. Locati, A. Bonetta, P.F. Conte, M. Airoldi, M. Merlano, P. Carlini, T. Ibrahim, C. Rossetto, P. Nicolai, R. Maroldi, S. Tonoli, P. Pronzato, S.M. Magrini, L. Licitra, A. Berruti.
Annals of Oncology, Volume 28, Issue suppl 5, 1 September 2017.
16. **Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer**
E. Orlandi, G. Infante, R. Granata, N. Iacovelli, R. Miceli, A. Cavallo, S. Alfieri, C. Bergamini, C. Resteghini, D. Galbiati, L. Locati, S. Tana, S. Naimo, C. Fallai, L. Licitra, P. Bossi.
6th ICHNO, March 2017, Volume 122, Supplement 1, Page 20.
17. **Definitive or adjuvant IMRT for locally advanced sinonasal tumors: outcome and prognostic factors E. Orlandi 1 Fondazione Irccs Istituto Nazionale Dei Tumori, Radiotherapy 2, Milan, Italy 1**
A. Cavallo, E. De Ponti, N.A. Iacovelli, P. Bossi, P. Nicolai, P. Castelnuovo, M. Guzzo, G. Calareso, S. Naimo, C. Bergamini, L. Locati, L. Licitra, E. Pignoli, C. Fallai.
Radiotherapy and Oncology 119:S519, April 2016 EP-1080.
18. **Nasopharyngeal Carcinoma: prognostic factors analysis in patients treated with IMRT and chemotherapy.ò**
N.A. Iacovelli, A. Cavallo, E. De Ponti, P. Bossi, S. Alfieri, G. Rossi, S. Naimo, C. Bergamini, S. Tana, L. Licitra, E. Pignoli, C. Fallai, E. Orlandi
Radiotherapy and Oncology 119:S518 EP-1078.
19. **Retreatment with Vismodegib is active in progressive advanced Basal Cell Carcinoma: first report from a single-Institution experience.**
S. Alfieri, P. Bossi, R. Granata, C. Bergamini, C. Resteghini, D. Galbiati, L. Locati, L. Licitra.
Annals of Oncology 27 (Supplement 4): 2016, M05.

20. **Ginger in the management of chemotherapy induced nausea and vomiting (CINV), in patients receiving high dose cisplatin: a multicenter, randomized, double-blind, placebo-controlled study.**
C. Bergamini, D. Cortinovis, S. Fatigoni, M. Cossu Rocca, A. Fabi, A. Iannace, A. Emiliani, M.A. Pessi, C.I. Ripamonti, S. Alfieri, R. Granata, F. Agustoni, P. Bidoli, F. Roila, F. Nolé, F. Macchi, L. Michellini, F. Montanaro, P. Bossi.
Annals of Oncology, 2016, Volume 27 Supplement 4, iv 57.
21. **Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer: a single center experience.**
R. Granata, P. Bossi, C. Bergamini, S. Alfieri, C. Resteghini, D. Galbiati, E. Orlandi, N.A. Iacovelli, C. Fallai, M. Guzzo, G. Infante, L. Locati, R. Miceli, L. Mariani, L. Licitra.
Annals of Oncology, 2016, Volume 27 Supplement 4, iv85–iv88.
22. **RANK expression in EBV associated nasopharyngeal cancer metastasis in non-endemic setting: a possible immunologic pathway to be targeted?**
C. Resteghini, S. Alfieri, P. Quattrone, F. Dominoni, G. Garzone, E. Orlandi, L. Locati, C. Bergamini, D. Galbiati, N.A. Iacovelli, L. Licitra, P. Bossi.
Annals of Oncology, 2016, Volume 27 Supplement 4, iv85–iv88, L04.
23. **Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer patients.**
C. Villa, M. Meregaglia, C. Rognogni, P. Pistillo, E. Orlandi, A. Iacovelli, R. Granata, S. Alfieri, C. Bergamini, C. Resteghini, L. Locati, P. Bossi, M. Guzzo, L. Licitra, F. Favales.
Annals of Oncology, 2016, Volume 27 Supplement 4, iv85–iv88, L09.
24. **An added value to Multidisciplinary Team: does a Tutor help to manage head and neck cancer patients?**
P. Cassini, S. Alfieri, P. Bossi, C. Bergamini, R. Granata, C. Resteghini, D. Galbiati, N.A. Iacovelli, E. Orlandi, F. Favales, C. Villa, P. Pistillo, L. Locati, L. Licitra.
Annals of Oncology, 2016, Volume 27 Supplement 4, iv85–iv88, L10.
25. **Treatment-associated mortality in head and neck cancer receiving chemotherapy and radiation: Meta-analysis of published trials.**
Paolo Bossi, Carlo Resteghini, Michela Cinquini, Cristiana Bergamini, Ester Orlandi, Laura D. Locati, Roberta Granata, Salvatore Alfieri, Nicola Alessandro Iacovelli, Carlo Fallai, Lisa F. Licitra.
Journal of Clinical Oncology 33(15_suppl):6062-6062, May 2015.
26. **Circulating pretreatment Epstein Barr Virus DNA quantification as a prognostic factor in nasopharyngeal cancer patients in a non endemic area.**
S Alfieri, C Resteghini, L Pala, S Marecaglia, NA Iacovelli, E Orlandi, A Cavallo, A Gloghini, GP Gesù, S Racca, R Dvir, D Morelli, F Taverna, P Quattrone, C Bergamini, R Granata, MC Cau, LD Locati, L Licitra, P Bossi.
Annals of Oncology 2015, 26 (Supplement 6): vi 67 - vi 68, 2015.
20. **Circulating pretreatment Epstein Barr Virus DNA quantification as a prognostic factor in nasopharyngeal cancer patients in a non endemic area.**
S. Alfieri, C. Resteghini, L. Pala, S. Marcegaglia, N. A. Iacovelli, E. Orlandi, A. Gloghini, G.P. Gesù, D. Fanti, S. Racca, R. Dvir, D. Morelli, F. Taverna, P. Quattrone, C. Bergamini, R. Granata, M.C.Cau, L.D. Locati, L.F. Licitra and P. Bossi.
Journal of Clinical Oncology, 2015 ASCO Annual Meeting (May 29 - June 2, 2015). Vol 33, No 15 suppl (May 20 Supplement), 2015: e17054.
27. **Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer.**
P. Bossi, E Orlandi, R Granata, P Quattrone, P Battaglia, D Lombardi, L Pala, M Barbara, P Nicolai, P Castelnuovo, M Guzzo, L Locati, C Resteghini, S Alfieri, M Imbimbo, NA Iacovelli, G Calareso, C Bergamini, L Licitra.
Annals of Oncology 2015, 26 (Supplement 6): vi 68, 2015.
28. **Site of metastatic disease influence adenoid cystic cancer (ACC) patient's outcome.**
MC Cau, S Alfieri, S Lo Vullo, C Bergamini, P Bossi, C Resteghini, M Imbimbo, M Siano, R Granata, L Licitra, L Locati.
Annals of Oncology 2015, 26 (Supplement 6): vi 68, 2015.

29. **Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): a retrospective study.**
C Resteghini, M Siano, MC Cau, S Alfieri, C Bergamini, R Granata, R Miceli, G Infante, N Imbimbo, L Locati, L Licitra, P Bossi.
Annals of Oncology 2015, 26 (Supplement 6): vi 70, 2015.
30. **Transarterial (chemo)embolization and radiofrequency ablation for patients with hepatic metastases (mts) of head and neck carcinoma (HNC) resistant to systemic treatment.**
R Granata, C Bergamini, G Calareso, T Cascella, P Bossi.
Annals of Oncology 2015, 26 (Supplement 6): vi 72, 2015.
31. **Incidence of pneumonia in hospitalized head and neck cancer patients treated by chemoradiation.**
Bergamini C, Bossi P, Granata R, Alfieri S, Imbimbo M, Pala L, Locati L, Resteghini C, Orlandi E, Iacovelli NA, Fallai C, Licitra L.
Publication in the AIOM 2014 Congress Abstract Book, a supplement to the official AIOM journal Annals of Oncology.
32. **Up-regulation of RAS pathway could predict the risk of distant metastases in HPV+ oropharynx cancer.**
L.D. Locati, L. De Cecco, F. Perrone, B. Cortelazzi, A. Gloghini, C. Volpi, S. Pilotti, R. Granata, P. Bossi, E. Orlandi, C. Resteghini, S. Alfieri, C. Bergamini, M. C. Cau, M. Imbimbo, P. Quattrone, S. Canevari, L.F. Licitra.
Publication in the AIOM 2014 Congress Abstract Book, a supplement to the official AIOM journal Annals of Oncology.
33. **Opioids – base therapy for oral mucositis (OM) – related pain during curative chemoradiotherapy (CT – RT) in oropharyngeal cancer (OPC) patients.**
Alfieri S, Ripamonti C, Marcegaglia S, Granata R, Iacovelli NA, Orlandi E, Bergamini C, Imbimbo M, Pala L, Resteghini C, Mirabile A, Locati L, Licitra L, Bossi P.
Publication in the AIOM 2014 Congress Abstract Book, a supplement to the official AIOM journal Annals of Oncology.
34. **Identification of a gene expression profile associated to progression – free survival (PFS) in relaps or metastatic (RM) head an neck squamous cell cancer (HNSCC) patients (pts) treated with first line cetuximab and platinum therapy.**
P. Bossi, De Cecco L, Perrone F, Cortelazzi B, Cossu Rocca M, Siano M, Sponghini A, Bergamini C, Locati L, Mirabile A, Granata R, Resteghini C, Pilotti S, Cancevari S, Licitra LF.
Publication in the ESMO 2013 Congress Abstract Book, a supplement to the official ESMO journal Annals of Oncology.
35. **Surveillance of Head and Neck Cancer (HNC) Patients: Clinical and Radiological Exams or Symptom Driven Follow Up?**
M Imbimbo, P Bossi, P Potepan, C Fallai, G Scaramellini, L Locati, C Bergamini, R Granata, A Mirabile, L Licitra.
Radiotherapy and Oncology. 2013 ISSN: 0167-8140, Vol: 106, Page: S16
36. **Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy.**
Paolo Bossi, Loris De Cecco, Federica Perrone, Barbara Cortelazzi, Maria Cossu Rocca, Siano Marco, Andrea Sponghini, Cristiana Bergamini, Laura D. Locati, Aurora Mirabile, Roberta Granata, Carlo Resteghini, Silvana Pilotti, Silvana Canevari, Lisa F. Licitra.
Journal of Clinical Oncology, co.2013.31.15_suppl.602 6027
37. **Activity and Safety of Vinorelbine in Adenoid Cystic Carcinoma: A Single Institution Retrospective Case Series.**
L Locati, M Imbimbo, P Bossi, C Bergamini, R Granata, A Mirabile, C Resteghini, B Bocci, L Licitra.
Radiotherapy and Oncology, ICHNO, 2013 Volume 106, Supplement 1, Pages S47 – S 48.

38. **Sorafenib in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): An investigator initiated phase II trial.**
Locati LD, Bossi P, Civelli EM, Perrone F, Bergamini C, Cortelazzi B, Quattrone P, Imbimbo M, Mirabile A, Granata R, Resteghini C, Mariani L, Tosarello D, Cassani C, Marchianò A, Saibene G, Pilotti S.
Ann Oncol. 2012 Sep; 23 Suppl 10:x328-33.
39. **Healthcare – associated infections (HAIs) in head and neck carcinoma patients: monoinstitutional analysis 2005 – 2009.**
Mirabile, C. Vismara, P. Bossi, L. Locati, C. Bergamini, R. Granata, D. Morelli, P. Scarpellini, L. Licitra.
Publication in the ESMO 2012 Congress Abstract Book, number 10190.
40. **Prognostic correlation of nutritional factors and c-reactive protein (CRP) in locally advanced head and neck carcinoma (LAHNC) treated with definitive or postoperative chemoradiation (CRT).**
Bergamini, P. Bossi, L. Locati, R. Granata, C. Resteghini, M. Imbimbo, E. Orlandi, C. Gavazzi, L. Licitra.
Publication in the ESMO 2012 Congress Abstract Book, a supplement to the official ESMO journal *Annals of Oncology*.
41. **Multidisciplinary team (MDT) for the first visit of head and neck cancer (HNC) outpatients: Istituto Nazionale dei Tumori experience.**
C Bergamini et al.
Publication in the AIOM 2012 Congress Abstract Book, a supplement to the official AIOM journal *Annals of Oncology*.
42. **The phase III study INTERCEPTOR in locally advanced head and neck cancer (LA-HNC). Preliminary safety report.**
M.C. Merlano, S. Vecchio, A. Bacigalupo, N. Denaro, E.G. Russi, M. Benasso, O Vigo. Ostellino6, M Rampino, L Canobbio8, A Grimaldi9, F Blengio, L Berretta, S Bui, N D'Abbioero, M D'Amico, G. Numico, C. Bergamini, E. Orlandi, M. Aieta. *Annals of Oncology* 09/2015; 51(suppl 6):S560.
43. **Locally advanced nasal cavity and ethmoid carcinoma: induction chemotherapy followed by multimodal treatment in a monoinstitutional series of patients.**
P. Bossi, D. Locati, C. Fallai, L. Porcu, G. Cantù, E. Orlandi, C. Bergamini, R. Granata, A. Mirabile, M. Franceschini, P. Potepan, P. Quattrone, P. Olmi, L. Licitra.
Radiotherapy and Oncology, Volume 98, Supplement 1, February 2011, Page S9.
44. **Survival of patient with oropharyngeal cancer according to HPV status, smoke and tumor presentation: an Italian validation study.**
R Granata, F Perrone, R Miceli, M Franceschini, E Orlandi, P Bossi, L Locati, C Bergamini, Calderone, A Mirabile, B Cortellazzi, S Pilotti, L Mariani, P Oli, KK Ang, L Licitra.
Ann Oncol (2010) 21(suppl 8): S58 – S59; D4.
45. **A natural history of a series of radioactive iodine (131I-RAI)-resistant advanced differentiated thyroid cancer (DTC).**
LD Locati, L Porcu, E Seregni, R Granata, P Bossi, C. Bergamini, A Mirabile, V Torri, E Bombardieri, L Licitra.
Ann Oncol (2010) 21(suppl 8): viii314-viii328; 1054.
46. **Samital in prophylaxis of chemo-radiation (CT – RT) induced mucositis in head and neck squamocellular cancer patients (pts): results of a prospective monoinstitutional phase II trial.**
C Bergamini, P Bossi, A Mirabile, E Orlandi, M Franceschini, P Olmi, R Granata, LD Locati, L Licitra.
Ann Oncol (2010) 21(suppl 8): viii314-viii328; 1055.
47. **Prognostic factors influencing outcome of patients with recurrent or metastatic carcinoma (R&M) of the head and neck: results of an Italian monoinstitutional study.**
A Mirabile, R Calderone, R Miceli, F Mattana, L Locati, P Bossi, C Bergamini, R Granata, L Mariani, L Licitra.
Ann Oncol (2010) 21(suppl 8): viii314-viii328; 1044P.

48. **Phase I Study of Concurrent Pemetrexed, Cetuximab and Radiation therapy with or without Cisplatin in patients with locally advanced squamous cell carcinoma on the head and neck (SCCHN).**
L Licitra, C Bergamini, P Olmi, V Soldatenkova, S Ameryckx, F Russo.
Ann Oncol (2010) 21(suppl 8): viii314-viii328; 1025D.
49. **Induction chemotherapy within a multimodality treatment of nasal cavity and ethmoid sinus malignant epithelial tumors: report of an homogeneous series of patients.**
P. Bossi, R. Calderone, G. Cantù, P. Olmi, P. Quattrone, L. Locati, C. Bergamini, R. Granata, P. Potepan, L. Licitra.
EJC Supplements 7(2):480-481 - September 2009.
50. **Locally advanced nasal cavity and ethmoid carcinoma: induction chemotherapy followed by multimodal treatment in a monoinstitutional series of patients**
P. Bossi, D. Locati, C. Fallai, L. Porcu, G. Cantù, E. Orlandi, C. Bergamini, R. Granata, A. Mirabile, M. Franceschini, P. Potepan, P. Quattrone, P. Olmi, L. Licitra
Radiotherapy. February 2011 Volume 98, Supplement 1, Page S9.
51. **TPF induction chemotherapy (CT) followed by concomitant cisplatin/radiotherapy (cCTRT) in locally advanced nasopharyngeal cancer (LANPC).**
P. Bossi, D. Parolini, C. Bergamini, L. D. Locati, E. Orlandi, M. Franceschini, M. Palazzi, P. Olmi, P. Potepan, L. Licitra.
J Clin Oncol 27:15s, 2009 (suppl; abstr 6046)
52. **Cisplatin dose intensity correlates with outcome in patients with locally advanced head and neck squamous cell carcinoma receiving concurrent cisplatin based chemoradiation: a multi-institutional experience.**
Granata R, Pond G, Kim J, Siu LL, Olmi P, Orlandi E, Bossi P, Locati L, Bergamini C, Calderone RG, Potepan P, Quattrone P, Licitra L.
Annals of Oncology 20 (Supplement 8): viii5–viii19, 2009.
53. **Acute Toxicity and efficacy of concomitant chemoradiotherapy in head and neck cancer (HNC) pts > 70 years old. A retrospective study of a single Institution experience.**
Locati L.D., Liberatoscioli C, Calderone RG, Orlandi E, Franceschini M, Bossi P, Bergamini C, Granata R, Fallai C, Olmi P. and Licitra L.
Annals of oncology; 2008, V19; Suppl 9: ix60;F19.
54. **Induction chemotherapy (CT) in locally advanced nasopharyngeal cancer (LANPC): results of three prospective consecutive phase II trials.**
Bergamini C, Bossi P, Granata R, Orlandi E, Locati LD, Liberatoscioli C, Calderone RG, Potepan P, Palazzi M, Olmi P and Licitra L.
Annals of oncology; 2008, V19; Suppl 9: ix60;F13.
55. **Definitive or postoperative radiotherapy with or without chemotherapy for head and neck cancer patients > 70 years old: experience of a single institutional.**
Orlandi E, Cerrotta M, Franceschini M, Bergamini C, Locati L, Licitra L and Olmi P.
Oncology Hematology. Incorporating Geriatric Oncology. V68, Suppl 2, October 2008; S52, p70.
56. **Feasibility and activity of docetaxel, cisplatinum and 5-fluorouracil (TPF) induction chemotherapy followed by concurrent chemo-radiotherapy (included IMRT) in locally advanced nasopharyngeal cancer (LANPC).**
Bergamini C, Bossi P, Orlandi E, Locati L, Liberatoscioli C, Fallai C, Palazzi M, Olmi P, Licitra L.
Annals of Oncology, 2007; Suppl 11: xi83, D122.
57. **Relationship between parotid glands dose and salivary toxicity in patients receiving intensity modulated radiation therapy (IMRT) and chemotherapy for nasopharyngeal carcinoma: preliminary results.**
Orlandi E, Palazzi M, Pignoli E, Tomatis S, Sangalli C, Bossi P, Bergamini C, Locati L, Licitra L, Olmi P.
Abstract from ESTRO 25. October 8-12, 2006. Leipzig, Germany.
Radiotherapy Oncology, 2006 Oct; 81 Suppl 1: 8; S1-533.

- 58. Optimizing the treatment of nasopharyngeal cancer: an update of the Milan experience including IMRT and chemotherapy intensification.**
Palazzi M, Tomatis S, Orlandi E, Bossi P, Guzzo M, Potepan P, Pignoli E, Bergamini C, Licitra L, Scaramellini G, Cantù G, Olmi P.
Radiotherapy Oncology, 2006 Oct; 81 Suppl 1: 8p preceding S1, S1 – 533.
- 59. Anti-androgen therapy in recurrent and/or metastatic salivary glands carcinoma (RSGC).**
LD Locati, B. Bossi, G.R. Rinaldi, C. Bergamini, Q. Quattrone, S. Staurengo, S. Pilotti, L. Licitra.
Ann Oncol (May 2005) 16(suppl 3): iii11-iii13, P404.
- 60. Treatment of advanced/metastatic colorectal carcinoma with capecitabine: a single institution experience.**
C. Bergamini, F. Onida, B. Galassi, N. Frisia, M. Tomirotti.
Annals of Oncology, volume 15, 2004 sup. 2 pag ii65.

Annex 3: List of **ABSTRACT**, in Italian language:

- 1. Carcinoma del rinofaringe: analisi dei fattori prognostici in una casistica di 149 pazienti consecutivi, trattati con tecniche di radioterapia ad intensità modulata e chemioterapia.**
Ester Orlandi, Nicola Alessandro Iacovelli, Paolo Bossi, Elena DE Ponti, Salvatore Alfieri, Mauro Carrara, Tommaso Giandini, Francesca Bassani, Roberta Granata, Cristiana Bergamini, Laura Locati, Marco Guzzo, Lisa Licitra, Emanuela Pignoli, Gianstefano Gardani, Carlo Fallai.
AIRO 2014; abstract N. 0211.
- 2. Reirradiazione nei tumori del distretto testa e collo: esperienza dell'Istituto Nazionale Tumori di Milano.**
E. Iannacone, S. Takanen, T. Giandini, E. De Ponti, C. Falli, S. Tana, E. Pignoli, V. Mongioj, M. Franceschini, P. Bossi, L. Locati, C. Bergamini, G. Scaramellini, M. Guzzo, L. Licitra, E. Orlandi.
XIII Congresso AIRO, 07/06/2013 ID N 02706.

Annex 4: **HAND-BOOK**, in English

Role of HPV infections in head and neck cancer

Lisa Licitra, Laura D Locati, C Bergamini, Paolo Bossi.
Current Multidisciplinary Oncology: Head and Neck Cancer.
Executive Editor. Demos Medical Publishing. USA.

Annex 5: **HAND-BOOK**, in Italian language

- 1. Il carcinoma adenoido-cistico nel distretto cervico-facciale**
Quaderni di aggiornamento dell'AOO
Realizzazione editoriale e stampa: TorGraf.
Biologia, genetica e fattori prognostici: M.C. Cau, S. Alfieri, C. Bergamini E. Orlandi, L. Licitra, L.D. Locati. Pag 59.
- 2. Tumori della Testa e del collo**
Collana di Immuno-Oncologia
Il Pensiero Scientifico Editore.
Volume 5. Pagina 1.
- 3. Trattamento dei tumori testa-collo: standard di terapia ed effetti secondari.**
Cristiana Bergamini e Lisa Licitra.
Advances in Supportive Care in Oncology; Vol 2, N 3, July – September 2012.
- 4. L'utilizzo di fentanil spray nasale nella disfagia dolorosa indotta da radio-chemioterapia per tumori del distretto testa - collo.**
Paolo Bossi, Cristiana Bergamini, Roberta Granata, Laura Locati, Aurora Mirabile, Carlo Resteghini, Lisa Licitra.
Content Ed Net. International medical publish solutions.
Maggio, 2012; pp 28 - 30.
- 5. Disposizioni per garantire l'accesso alle cure palliative e alla terapia del dolore, dalla Legge 38/2010 alla pratica clinica.**
Content ed. Net, 2012, p28 – 32.
- 6. Trattamento del dolore cronico in paziente con carcinoma del cavo orale operato e chemio radiotrattato.**
A Picone, A Mirabile, C Bergamini, M Franceschini, R Granata, P Bossi, P Olmi, L Licitra.
L'uso degli oppiacei nella pratica clinica.
InScience Communications. A Wolters Kluwer business.
Anno XL, N. 5, maggio 2010; pp 124 – 125.
- 7. I tumori della testa e del collo**
Bergamini C, Licitra L, Olmi P.
Fondazione AIOM; Intermedia Editore, pp 1 - 23.

ANNEX 6: CLINICAL TRIALS

At the moment, she is sub-investigator for TRIAL:

- An open-label, multicenter, dose-escalation, phase Ia/Ib study to evaluate safety, pharmacokinetics, and therapeutic activity of RO6874281, an immunocytokine consisting of interleukin 2 variant (IL-2v) targeting fibroblast activation protein- α (FAP), as a single agent (PART A) or in combination with trastuzumab or cetuximab (PART C). Roche BP29842. Eudra CT: 2015-002251-97.
- Phase II trial of abiraterone acetate in patients with relapsed and/or metastatic, castration resistant salivary gland cancers. EUDRACT N° 2014-001274-34.
- A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid. Cancer Patients, Exelixis 113,446. Protocol number: XL184-401.
- The CONFRONT Phase I – II Trial: ACTivatiON oF immune RespONse in paTients with R-M Head and Neck Cancer. Multimodality immunotherapy with Avelumab, short course radiotherapy and Cyclophosphamide in Head and Neck cancer. EudraCT n. 2017-000353-39
- A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs). Intergroup Study (EORTC-1206-HNCG). (EudraCT number 2013-000314-38) (NCT01969578)
- A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck "UPSTREAM". EORTC 1559 Upstream. Eudra CT: 2017-000086-74.
- A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412). IND NUMBER: 122,325. EudraCT NUMBER: 2016-003934-25.
- A phase 2 study of REGN 2810, a fully human monoclonal antibody to programmed death-1, in patients with advanced basal cell carcinoma who experienced progression of disease on hedgehog pathway inhibitor therapy, or were intolerant of prior hedgehog pathway inhibitor therapy. IND Number: 127100. EudraCT Number: 2016-003122-16.
- A phase III, multicenter, randomized, double-blind, placebo controlled study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. Protocol number: WO40242. EUDRACT number: 2017-003302-40. Ind number: 135963.
- A multicenter randomized trial to evaluate the efficacy of Fentanyl pectin nasal spray (FPNS) versus Physician Choice (PC) - Usual Care (UC), in reducing incidental predictable breakthrough pain (IP-BTP) at swallowing in patients with head and neck cancer undergoing radiotherapy. EudraCT number: 2015-005110-30.
- A Prospective Observational Study for the Development and Validation of New Prognostic Models in Head and Neck Cancer Patients for Decision Support.
- Head and neck cancer patients' preference: developing, validating and testing a multi-cultural questionnaire in different treatment settings. Priority HN1/2.
- Intergroup Study (EORTC-1206-HNCG) (EudraCT number 2013-000314-38) (NCT01969578): A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs).

In the past, she was sub-investigator for TRIAL:

- Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients. AstraZeneca. Eagle. Study Code D419LC00001.
- A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). AstraZeneca Kestrel D419LC00001. Study Code D4193C00002.
- A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. AstraZeneca Scores D5660C00004. Eudra CT 2015-002525-19.
- A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors. BMS CA223-001. EUDRACT Number 2016-001359-36.
- A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors. Clinical Protocol CA223001.
- An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). Clinical Protocol CA209651. IND Number: 125872. EUDRACT Number 2016-000725-39.
- A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). EUDRACT Number 2016-001645-64.
- A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. MSD Keynote 048. EudraCT NUMBER: 2014-003698-41.
- A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer. MSD Keynote 040. EudraCT NUMBER: 2014-001749-26.
- Multidisciplinary approach for poor prognosis sinonasal tumors: Phase II study of chemotherapy, surgery, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in operable patients. SINTART1. EudraCT Number: 2013-000075-33.
- SINTART2. "Multidisciplinary approach for poor prognosis sinonasal tumors: Phase II study of chemotherapy, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in inoperable patients".
- Phase II study on Inlyta® (axitinib) in recurrent and/or metastatic salivary gland cancers (SGCs) of the upper aerodigestive tract. EUDRACT number: 2014-003227-21.
- Phase II Study: Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer. EUDRACT: 2011-002564 – 24.
- Efficacy and safety of single agent pan-HER inhibitor Dacomitinib in the treatment of locally advanced unresectable or metastatic squamous cell cancer of the skin or with clinical contraindication to surgery. EUDRACT N° 2014-002175-28.

- A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy. EORTC protocol 1209-EnTF. EudraCT number 2012-004295-19. NCT01788982.
- A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with NIVolumab in Subjects with Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) – NIVACTOR Study. EudraCT number: 2017-000562-30.
- Phase II study on Lenvatinib in recurrent and/or metastatic adenoid cystic carcinomas (ACC) of the salivary glands of the upper aerodigestive tract. EUDRACT NUMBER: 2015-000693-35. (NCT02860936).
- Clinical Protocol CA209141. An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN).
- HPV positive oropharyngeal cancer: characterization of immunological and viral profiles, and their role in the response to treatment.
- A randomized phase II study for tertiary prevention of squamocellular carcinoma of head and neck (SCCHN) with a dietary intervention.
- A randomized, double-blind, placebo controlled, mono-centre phase II study to evaluate the efficacy of treatment with ginseng in reducing fatigue in patients treated for head and neck Cancer.
- Phase II study on Inlyta® (axitinib) in recurrent and/or metastatic salivary gland cancers (SGCS) of the upper aerodigestive tract”
- Trial “TPF oral cavity, Italian study”. Phase II study of preoperative TPF chemotherapy in locally advanced resectable oral cavity squamous cell cancer in order to improve the rate of pathological complete response.
- Trial Cet-INT. “Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer (Italian clinical trial, phase II)”.
- The “RELIEVE 1” Study. “A Randomised, double-blind, placebo-controlled study to evaluate the Efficacy of two different dose levels of overprepitant (10 and 30 mg) compared with placebo on EGFR-induced intense pruritus in oncology subjects”.
- INTERCEPTOR TRIAL. “Induction chemotherapy followed by Cetuximab plus definitive radiotherapy versus radiation plus cisplatin”.
- A phase 2, multicenter, international, single arm study to assess the safety and efficacy of single agent cc-486 (oral azacitidine) in previously treated subjects with locally advanced or metastatic nasopharyngeal carcinoma.
- A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN). D4193R00002”.
- A randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma. LUX-Head & Neck 2.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer. Trial E7080-G000-303.
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™) 300 mg in Patients with Papillary or Poorly Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.

- Phase II multicenter randomized, double blind, placebo controlled study assessing the efficacy of buparlisib (BKM120) plus paclitaxel vs. placebo plus paclitaxel in patients with platinum pre-treated recurrent or metastatic head and neck squamous cell carcinoma.
- A phase II, open-label, randomized study of MEHD7945a versus cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck who have progressed during or following platinum-based chemotherapy. Trial MEHD7945A.
- A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum-based therapy. Trial LUX-Head & Neck 1.
- Randomized, Double-blind, Multicenter -Stage Adaptive Phase 3 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus the Chemotherapy Alone in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck who have Progressed on or after Prior Platinum-Based Chemotherapy. Trial REOLYSIN.
- Trial Vismodegib. “A single arm, open-label, phase II, multicentrum study, to assess the safety of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC)”.
- An International, Randomized, Double-Blind, Two-Arm Study to Evaluate the Safety and Efficacy of Vandetanib 150 and 300 mg/day in Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma with Progressive or Symptomatic Disease. Trial D4200C00097.
- A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer. Trial BAY 43-9006/14295.
- Phase II study of Pemetrexed in combination with Cisplatin and Cetuximab in recurrent and metastatic squamous cell carcinoma of the head and neck. Trial S123.
- Open-label, randomized, controlled Phase I/II study of cilengitide to evaluate the safety and efficacy of the combination of different regimens of cilengitide added to cisplatin, 5-FU, and cetuximab in subjects with recurrent/metastatic squamous cell cancer of the head and neck. Trial ADVANTAGE.
- An open label single arm trial investigating zalutumumab, a human monoclonal anti-EGF receptor antibody, in combination with best supportive care, in patients with non curable squamous cell carcinoma of the head and neck who have failed standard platinum-based chemotherapy. Trial GEN205.
- Prophylaxis of mucositis radiotherapy induced in the patients affected by neoplasia of head and neck cancer. Trial SAMITAL.
- Phase I/II study; concurrent pemetrexed, cetuximab and radiation therapy with or without cisplatin in patients with locally advanced SCCHN. Trial H3E – EW – S120.
- Phase III study; a randomized study of pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent and metastatic head and neck cancer. Trial clinical H3E – MC – JMHR.
- Italian clinical trial, phase III; radiotherapy associated to chemotherapy Cisplatin low dose *versus* Cisplatin + 5-Fluorouracil - in head and neck squamocellular carcinoma locally advanced. Trial Medusa.

Annex 7: CONGRESS

1. Progetto RUA, Milan, 3 October 2018. Auditor.
2. Il paziente anziano e il tumore testa – collo. Le sfide di un approccio multidisciplinare. Milan, 19 December 2017.
3. La cronicità nel paziente oncologico tra modelli di presa in carico e percorsi di cura: luci ed ombre. Milan, 2 December 2017. Auditor.
4. Corso di aggiornamento NICSO. Update in terapie di supporto e immunoterapia. Rome, 25 Nov 2017. Auditor.
5. Workshop Opdivo. Rome, 23 Nov 2017. Auditor. Sponsor BMS.
6. Rischio stress – lavoro. Milan, Edition 12/10/2017. Auditor.
7. Programma fase I: studio dei processi, SOP, norme di buona pratica clinica (GCP) e mantenimento dei requisiti richiesti da AIFA. Milan, 9 June 2017. Auditor.
8. Programma fase I: studio dei processi, SOP, norme di buona pratica clinica (GCP) e mantenimento dei requisiti richiesti da AIFA. Milan, from 7 July to 31 December 2016. Auditor.
9. Grandangolo in Oncologia. Focus su terapie di supporto 2017. Bologna. 9 May 2017. Relator.
10. BLS. Milan, 22 May 2017. Participant.
11. Continuità assistenziale nel paziente oncologico fragile. La riabilitazione oncologica al Pio Albergo Trivulzio. Milan, 06 April 2017. Relator.
12. Aggiornamenti in oncologia: iponatremia. Sponsor: Otsuka. Verona 26-27, January 2017. Auditor
13. XVIII Congresso Nazionale di Oncologia medica. Rome, 26 – 30 October 2016. Auditor.
14. Aggiornamento costante sull'andamento degli studi clinici – SC OM3. Milan, from 5 September to 31 December 2016. Auditor.
15. Consensus conference sulla global care del paziente con tumore testa-collo ricorrente/metastatico. Milan, 5 May 2016. Auditor.
16. Grandangolo in Oncologia. Focus su Terapie di Supporto 2016. Bologna, 9 – 10 May, 2016. Relator.
17. Look septic. Milan, 5 and 11 April 2016. Auditor.
18. Riunione WP 1 – Gruppo di Lavoro PDTA tumori testa e collo. 29 January 2016. Auditor.
19. La Legge 38/2010 e sua reale applicazione con i relativi risvolti clinico-organizzativi di gestione del paziente con dolore. Florence, 24 November 2015. Auditor.
20. Seminar on Nasopharyngeal Cancer. Milan, 12 November 2015. Auditor.
21. XVII Congresso Nazionale di Oncologia Medica. Rome, 25 October 2015. Auditor.
22. Skyline - Nuovi orizzonti delle terapie target nei tumori cutanei. Simposio Satellite. Roma, 24 October 2015. Auditor.
23. Update in head and neck oncology: post - ASCO meeting. Milan, 14 September 2015. No Sponsor. Auditor.
24. Hot topics in oncologia toracica: il mesotelioma pleurico. Rozzano (MI), 31/01/2015. No Sponsor. Auditor.

25. Consensus conference on salivary gland tumors Adenoid-cystic carcinoma and high grades neoplasms a common commitment towards the future. Brescia, 23 – 24/10/2014. No Sponsor. Auditor.
26. Master class in oncologia: management della SIADH. Ancona, 17/05/2014. Sponsor: Otsuka. Auditor.
27. Luci e ombre della terapia a target in oncologia: nuovi bersagli e “cardioncologia”. Reggio Emilia, 29 January 2014. No Sponsor. Auditor.
28. 2013: News in Oncology. Perugia, 5-6 July 2013. Sponsor: AIOM. Auditor.
29. La legge 38/2010 e sua reale applicazione con i relative risvolti clinico-organizzativi di gestione del paziente con dolore. Florence, 24 November 2012. Sponsor: Molteni Farmaceutici. Auditor.
30. Progetto di formazione sul campo tenutosi a Milano dal 1 marzo al 28 novembre 2012. No Sponsor. Participant.
31. Update on Oral Mucositis: Pathology, Diagnosis and Evaluation. 30 May 2012. Sponsor: Clinical Assistance Programs LLP. Auditor.
32. Il breakthrough cancer pain: dalla teoria alla pratica. Milan, 25 May 2012. Sponsor: GRÜNENTHAL PHARMA. Auditor.
33. Roche clinical trial portal site users tutorial. 10 May 2012. Sponsor: ePharmaSolutions. Auditor.
34. Terapie di supporto e palliative al paziente oncologico. Un approccio integrato di cura. Milan, 20 April 2012. Sponsor: AIOM. Auditor.
35. GCP e aspetti di qualità nella conduzione degli studi clinici. Milan, 3 April 2012. Sponsor: Novartis. Auditor.
36. Riunione di aggiornamento Linee guida ROL. Tumori testa e collo. Milan, 20 February 2012. No sponsor. Auditor.
37. Riunione di aggiornamento Linee guida ROL. Tumori testa e collo. Milan, 23 January 2012. No sponsor. Auditor.
38. Riunione di aggiornamento Linee guida ROL. Milano, 29 November 2011. No sponsor. Auditor.
39. Study MO25616, Investigators meeting. 23 June 2011. Sponsor: Roche. Auditor.
40. SCCHN EGFR Advisor’s Network meeting, April 1-2, 2011, Vienna, Austria. Sponsor: Merck. Serono Auditor.
41. Oral mucositis – induced pain during concomitant chemoradiotherapy for head and neck. Studio Mucositis AIFA. Milan, 18 February, 2011. Sponsor: AIFA. Auditor.
42. 4th EHNS, European Conference on Head and Neck Oncology. Athens, 3-6 March, 2010. Sponsor: UEMS. Auditor.
43. Cancer and Nutrition. Zurich, 20-21 March 2009. Sponsors ESMO and EUMS. Auditor.
44. Educational cancer convention. Lugano, 2-4July, 2009. Sponsors: European School of Oncology and Ministero della Salute. Auditor.
45. European Head & Neck Course. Amsterdam, 14-16 October 2009. No sponsor. Participant.
46. Percorso formativo ECM per un paziente senza dolore. Campi Bisenzio (FI), 18 April 2009. Sponsor: Molteni. Participant.
47. X Congresso Nazionale di Oncologia medica, AIOM. Verona, 11-14 October 2008. Sponsor: AIOM. Auditor.
48. Investigators meeting Genmab GEN205. Rome, 3 October 2008. Sponsor: Genmab. Auditor.

49. Percorso formativo ECM per un paziente senza dolore. Poggibonsi (SI), 13-14 June 2008. Sponsor: Molteni. Auditor.
50. Advanced Head and Neck Tumors: New Trends in Medical and Radiotherapy Modalities. Milan, 10-11 April 2008. No Sponsor. Auditor.
51. 2° Forum Italiano: Ricerca e Qualità di Cura nel Paziente con Dolore Cronico da Cancro. Roma, 29 February and 1 March 2008. Sponsor: Wolters Kluwer. Auditor.
52. 1ère journée de Cancerologie ORL. Villejuif, 10 September 2007. Sponsor: Sanofi Aventis. Auditor.
53. IX Congresso Nazionale di Oncologia medica, AIOM. Palermo, 12-15 October 2007. Relator.
54. 3ème rencontre de pathologie mammaire de l'IGR. Villejuif, 19 June 2007. No sponsor. Auditor.
55. Investigators meeting. Protocolli nazionali. Tumori della testa e collo. Candiolo, 15 June 2007. No sponsor. Relator.
56. Investigators meeting per il progetto medusa: protocolli nazionali per il trattamento dei tumori testa e collo. Milan, 26 March 2007. No sponsor. Auditor.
57. L'oncologia medica dei tumori rari. Journal club 2006. Milan, 18-19 October 2006. Sponsor: Novartis. Auditor.
58. Simposio su Target Therapy nei tumori Testa – collo. Consensus conference per la terapia del Carcinoma Laringeo. Milan, 12-13 October 2006. No sponsor. Auditor.
59. Le basi della nutrizione artificiale. Triuggio (Milan), 28-29 September 2006. Sponsor: SINPE. Auditor.
60. Grandangolo 2005: un anno di oncologia. VII edizione. Bergamo, 13-14 December 2005. Sponsor: Accademia nazionale di medicina. Auditor.
61. Investigators meeting sui protocolli nazionali del Gruppo Italiano per il Trattamento dei Tumori testa e collo. Rome, 28 November 2005. Relator.
62. EGFR e target therapy: il ruolo sinergico tra l'oncologo e l'anatomopatologo. Bergamo, 30 May 2005. Sponsor: Devital Service Spa. Auditor.
63. Aspetti innovativi nel trattamento dei tumori. Milan, 15 November 2003. Sponsor: AIOM. Auditor.
64. La ricerca al servizio della persona. Milan, 12 May 2003. No sponsor. Auditor.

I hereby authorize the use of my personal data in accordance to the **GDPR** 679/16.

Doc. Cristiana Bergamini